US2014274937A1PendingUtilityA1
Methods of treating hematologic cancers
Est. expiryAug 4, 2029(~3 yrs left)· nominal 20-yr term from priority
A61K 31/56A61K 31/52A61K 31/196A61K 31/7076A61P 35/02A61K 31/353A61P 35/00A61K 45/06A61K 31/4164
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This disclosure relates to the treatment of hematologic cancers, for example, cancers of the blood, by methods that include administration of EGCG and at least one of a purine nucleoside analog and an alkylating agent. In particular, methods of treating chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) are described.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating a hematologic cancer in a subject comprising the steps of:
(a) administering to the subject an effective amount of EGCG, or a pharmaceutically acceptable salt or derivative thereof; and (b) administering to the subject an effective amount of one or more of a purine nucleoside analog, or a pharmaceutically acceptable salt or derivative thereof, and an alkylating agent, or a pharmaceutically acceptable salt or derivative thereofJoin the waitlist — get patent alerts
Track US2014274937A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.